These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36267268)

  • 1. Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study.
    Wang YS; Wang W; Zhang S; Zhang SY; Shen AZ; Wang W; Song HC; Yao HZ; Song RP; Meng FZ; Li L; Nashan B; Wang JZ; Liu LX
    Front Pharmacol; 2022; 13():1009612. PubMed ID: 36267268
    [No Abstract]   [Full Text] [Related]  

  • 2. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 4. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 6. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.
    Huang A; Chen JF; Wu JZ; Gao Z; Shi YH; Fu XT; Zhang X; Liu WR; Gao Q; Sun HC; Shi GM; Fan J; Ding ZB; Zhou J
    J Oncol; 2022; 2022():9138195. PubMed ID: 36405248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.
    Fu H; Lv M; Liu H; Sun Y; Zhang Y; Mo X; Han T; Wang F; Yan C; Wang Y; Kong J; Han W; Chen H; Chen Y; Chen Y; Xu L; Liu K; Huang X; Zhang X
    Bone Marrow Transplant; 2023 Dec; 58(12):1368-1376. PubMed ID: 37679646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
    Eguchi Y; Takahashi H; Mappa S; Santagostino E
    Hepatol Res; 2022 Apr; 52(4):371-380. PubMed ID: 35134259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li C; Li X; Huang F; Yang J; Wu A; Wang L; Qin D; Zou W; Wu J
    Front Pharmacol; 2019; 10():829. PubMed ID: 31402863
    [No Abstract]   [Full Text] [Related]  

  • 15. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
    Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
    Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.
    Satapathy SK; Sundaram V; Shiffman ML; Jamieson BD
    Medicine (Baltimore); 2023 Oct; 102(40):e35208. PubMed ID: 37800793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.